Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2417918 | 0.86 | ACHE (0.42) | ACHECYP19A1HTR2CHTR2AHTR2B | |
| SCHEMBL5612544 | 0.81 | CYP19A1 (0.40) | ACHECYP19A1HTR2CMAPT | |
| SCHEMBL21887680 | 0.78 | ACHE (0.69) | ACHEHTR2CHTR2AHTR2BNOTUM | |
| SCHEMBL5616667 | 0.75 | KDM4E (0.40) | ACHECYP19A1NOTUMMAPTKDM4E | |
| SCHEMBL16552788 | 0.75 | CYP19A1 (0.47) | ACHECYP19A1MEN1CYP3A4MAPT | |
| SCHEMBL16552796 | 0.73 | CYP19A1 (0.44) | ACHECYP19A1 | |
| SCHEMBL1658072 | 0.72 | ACHE (0.47) | ACHE | |
| SCHEMBL2416616 | 0.71 | ACHE (0.43) | ACHECYP19A1HTR2C | |
| SCHEMBL2420985 | 0.70 | ACHE (0.42) | ACHECYP19A1HTR2CKDM4E | |
| SCHEMBL5952947 | 0.69 | METAP1 (0.35) | ACHEHTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008057309-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057309-A2 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | MERCK & CO., INC. | 2007-12-20 | — | — | US | disclosed |
| EP-1819656-A2 | SYNTHESIS OF 1,5-DISTRIBUTED-2-HYDROXY-GIBBATETRAEN-6-ONES | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1809594-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7151196-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-12-19 | — | — | US | disclosed |
| WO-2006050399-A2 | SYNTHESIS OF 1,5-DISUBSTITUTED-2-HYDROXY-GIBBATETRAEN-6-ONES | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006050402-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094779-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094779-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ACHE 642/4885CYP19A1 44/4885HTR2C 954/4885 |
| US-20070293706-A1 | Synthesis Of 1,5-Disubstituted-2-Hydroxy-Gibbatetraen-6-Ones | ESR1, GPER1, CYP19A1 | ACHE 1762/4885CYP19A1 3/4885HTR2C 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.